Micro
Emerging
Active
Kemajuan FDA MDCXW dan perluasan prospek klinis
Narasi baru dengan cakupan terbatas — masih terbentuk.
Skor
0,5
Kecepatan
▲ 0,0
Artikel
1
Sumber
1
Linimasa Sentimen
Linimasa Peristiwa
Mei 19, 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Neutral
Hipotesis
Pending
Jatuh Tempo: 18 Juli 2026
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
Jatuh Tempo: 15 Nov. 2026
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
Jatuh Tempo: 17 Agu 2026
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
Lini Waktu
Terakhir DiperbaruiMei 19, 2026